[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627149":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Panic Disorder (PD)",null,"Adult participants (18-65 years) diagnosed with panic disorder (PD) according to DSM-5-TR criteria. All of the subjects with PD was drug-naive. Subjects were evaluated at baseline. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters. Clinical assessments in the PD group included the DSM-5 Panic Disorder Severity Scale (Adult Form). Sociodemographic and clinical data were recorded for all participants.",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy Control (HC)","Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Mehmet Hamdi ÖRÜM, MD, Ass. Prof., Psychiatrist","CONTACT","+905382207558","mhorum@hotmail.com",[22],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"countryCode":10,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Elazığ Mental Health and Diseases Hospital Psychiatry Clinic","RECRUITING","Elâzığ","23200","Turkey (Türkiye)",{"type":29,"coordinates":30},"Point",[31,32],39.22321,38.67431,{"lat":32,"lon":31},[35],{"name":36,"role":18,"phone":19,"phoneExt":10,"email":20},"Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mehmet Hamdi ÖRÜM","MD, Assoc. Prof, Psychiatrist","100627149","il-33-sst2-and-crp-in-panic-disorder-100627149",false,"NCT07444879","IL-33, sST2, and CRP in Panic Disorder","Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study","1. For Panic Disorder (PD) Group:\n\n   \\*Inclusion Criteria:\n   * Being between 18-65 years of age\n   * Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder\n   * Not having previously used any medication for psychiatric purposes (drug-naive)\n   * Not having any additional active psychiatric disorders besides PD at the current presentation\n   * Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n   * Not having taken any medication or supplements in the last month\n   * Completing sociodemographic and scale data fully\n   * Volunteering to participate in the study\n\n   For PD Group:\n\n   \\*Exclusion Criteria:\n\n   • Being outside the 18-65 age range\n\n   • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health\n\n   • Having a history of psychiatric medication use\n\n   • Having an additional psychiatric disorder besides PD at the current application\n\n   • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer\n\n   • Patients with a body mass index (BMI) \\\u003C18.5 kg\u002Fm² and \\>29.9 kg\u002Fm²\n   * Taking any medication or supplement in the last month\n   * Incomplete completion of sociodemographic and scale data\n   * Not volunteering to participate in the study\n2. For Healthy Control Group:\n\n   * Inclusion Criteria:\n\n     * Being between 18-65 years of age\n     * Not having any active psychiatric disorder\n     * Not having previously used any medication for psychiatric purposes (drug-naive)\n     * Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n     * Not having taken any medication or supplement in the last month\n     * Completing sociodemographic and scale data fully\n     * Volunteering to participate in the study\n\nFor Healthy Control Group:\n\n\\*Exclusion Criteria:\n\n* Being outside the 18-65 age range\n* Having any active psychiatric disorder\n* Having a history of using psychiatric medication\n* Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n* Patients with a body mass index (BMI) \\\u003C 18.5 kg\u002Fm² and \\> 29.9 kg\u002Fm²\n* Taking any medication or supplement in the last month\n* Incomplete completion of sociodemographic and scale data\n* Not volunteering to participate in the study",true,"ALL","18 Years","65 Years",{"count":53,"type":54},80,"ESTIMATED","OBSERVATIONAL","Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33\u002FsST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.",[58],"Panic Disorder",[58,60,61,62,63,64,65],"Interleukin-33","IL-33","Soluble Suppressor Tumorogenicity-2","sST2","CRP","C-Reactive Protein","2026-03-02",{"date":68,"type":69},"2026-03-04","ACTUAL",{"date":71,"type":69},"2025-07-07",{"date":73,"type":54},"2026-03-23",{"name":5,"class":6},1]